AstraZeneca has received more than $1 billion from the U.S. Health Department’s Biomedical Advanced Research and Development Authority (BARDA) to develop a coronavirus vaccine from the University of Oxford. Pascal Soriot, CEO of AstraZeneca, joins “Squawk Box” and CNBC’s Meg Tirrell to discuss the company’s efforts to develop a Covid-19 vaccine.
More Stories
Brazil rolls out COVID-19 vaccination plan
First Pfizer COVID-19 vaccine shipments to be delivered to US distribution sites starting Monday
CDC advisory panel recommends Covid-19 vaccine for people 16 and over